ArticleScience advances2023
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers.Nature communications · 2026Article
- Diverse Roles of Semaphorins on T Cell Activation, Differentiation, Migration, and Effector Functions.Cells · 2026Review
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Network pharmacology-guided optimization of Semen Sojae Praeparatum fermentation for enhanced anti-influenza efficacy.Scientific reports · 2026Article
- Semaphorins: from CD8⁺ T cells to cancer immunotherapy.Biomarker research · 2026Review
- Context-Dependent Dual Roles of the Plexin-B Family in Cancer Progression: Mechanisms and Therapeutic Implications.Cancer management and research · 2026Review
- Obstructive sleep apnea and lung cancer: molecular underpinnings and clinical translational prospects.Frontiers in cell and developmental biology · 2026Review
- Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.Human vaccines & immunotherapeutics · 2025Review
- Single-cell transcriptomics reveals dynamic reprogramming of testicular immunity inZoological research · 2025Article
- Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.Biomarker research · 2025Review
- On-Demand Controlled Release Multi-Drugs Delivery System for Spatiotemporally Synergizing Antitumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mutation of conserved MHC class I cytoplasmic tyrosine affects CD8+ T cell priming, effector function, and memory response.Frontiers in immunology · 2025Article
- Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis.eLife · 2024Article
- PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination.Cancer immunology research · 2024Article
- Interferon signaling and ferroptosis in tumor immunology and therapy.NPJ precision oncology · 2024Article
- Polyamines: the pivotal amines in influencing the tumor microenvironment.Discover oncology · 2024Review
- Sema6D forward signaling impairs T cell activation and proliferation in head and neck cancer.JCI insight · 2024Article
- Semaphorin 6 Family-An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis.Cancers · 2023Review
- Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance.International journal of molecular sciences · 2023Review
- Plexin B1 controls Treg numbers, limits allergic airway inflammation, and regulates mucins.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 9 institutions in 3 countries.
Yujiro NaitoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0003-0633-4936
Shohei KoyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-6897-9417
Kentaro MasuhiroDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-8785-1726
Takashi HiraiDepartment of Immunopathology, World Premier International Research Center (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan.
Takeshi UenamiDepartment of Thoracic Oncology, National Hospital Organization, Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.
Takako InoueDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Akio OsaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Hirotomo MachiyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Go WatanabeDivision of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Kashiwa,Chiba, and Tokyo, Japan.ORCID 0000-0002-4697-4949
Nicolas SaxKOTAI Biotechnologies Inc., Suita, Osaka, Japan.ORCID 0000-0003-3241-4737
Jordan VillaKOTAI Biotechnologies Inc., Suita, Osaka, Japan.ORCID 0000-0002-5052-7551
Yumi Kinugasa-KatayamaDepartment of Cellular Immunology, Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Osaka, Japan.
Satoshi NojimaDepartment of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-5124-0026
Moto YagaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0001-6649-6887
Yuki HosonoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Daisuke OkuzakiSingle Cell Genomics, Human Immunology, WPI, IFReC, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-4552-783X
Shingo SatohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-2798-4711
Takeshi TsudaDepartment of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-6861-1700
Yoshimitsu NakanishiDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0001-6172-6364
Yasuhiko SugaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-4906-8810
Takayoshi MoritaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kiyoharu FukushimaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-9767-7899
Masayuki NishideDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0001-6060-1228
Takayuki ShiroyamaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kotaro MiyakeDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-6441-1699
Kota IwahoriDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Haruhiko HirataDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-1134-7283
Izumi NagatomoDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0001-5382-4327
Yukihiro YanoDepartment of Thoracic Oncology, National Hospital Organization, Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.
Motohiro TamiyaDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Toru KumagaiDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Norihiko TakemotoDepartment of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0003-1285-9667
Hidenori InoharaDepartment of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Sho YamasakiLaboratory of Molecular Immunology, WPI, IFReC, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-5184-6917
Kazuo YamashitaKOTAI Biotechnologies Inc., Suita, Osaka, Japan.ORCID 0000-0002-7825-4719
Taiki AoshiDepartment of Cellular Immunology, Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Osaka, Japan.
Esra A AkbayDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-4149-2529
Naoki HosenIntegrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka, Japan.
Yasushi ShintaniDepartment of General Thoracic Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-2540-5288
Hyota TakamatsuDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-0382-5142
Masahide MoriDepartment of Thoracic Oncology, National Hospital Organization, Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.
Yoshito TakedaDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0003-4749-7117
The University of Osaka · JPOsaka International University · JPOsaka Gakuin University · JPOsaka International Cancer Institute · JPTagCyx Biotechnologies (Japan) · JPToneyama National Hospital · JPChiba Cancer Center · JPOsaka University of Human Sciences · JPThe University of Texas Southwestern Medical Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice, although the role of human Sema4A in the tumor microenvironment remains unclear. This study demonstrates that histologically Sema4A-positive non-small cell lung cancer (NSCLC) responded significantly better to anti-programmed cell death 1 (PD-1) antibody than Sema4A-negative NSCLC. Intriguingly, SEMA4A expression in human NSCLC was mainly derived from tumor cells and was associated with T cell activation. Sema4A promoted cytotoxicity and proliferation of tumor-specific CD8
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsSemaphorinsAnimalsAntibodies, BlockingCD8-Positive T-LymphocytesCell ProliferationHumansMiceProgrammed Cell Death 1 ReceptorTumor MicroenvironmentAntibodies, BlockingProgrammed Cell Death 1 ReceptorSEMA4A protein, humanSemaphorins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.